Aardvark Therapeutics, Inc. (NASDAQ:AARD – Free Report) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for shares of Aardvark Therapeutics in a note issued to investors on Monday, July 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.05) per share for the quarter, down from their previous forecast of ($0.95). HC Wainwright has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.46) per share. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.80) EPS, Q1 2027 earnings at ($0.72) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.35) EPS.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter.
Get Our Latest Stock Report on Aardvark Therapeutics
Aardvark Therapeutics Stock Performance
NASDAQ:AARD opened at $6.08 on Wednesday. The stock has a 50-day simple moving average of $4.82 and a 200-day simple moving average of $7.42. The stock has a market cap of $133.03 million, a P/E ratio of -1.89 and a beta of 3.93. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $17.94.
Hedge Funds Weigh In On Aardvark Therapeutics
A number of institutional investors have recently modified their holdings of AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Aardvark Therapeutics during the 2nd quarter worth $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at about $47,000. Persistent Asset Partners Ltd acquired a new stake in shares of Aardvark Therapeutics during the fourth quarter worth about $56,000. New York State Common Retirement Fund purchased a new position in shares of Aardvark Therapeutics during the second quarter worth about $99,000. Finally, MetLife Investment Management LLC acquired a new position in Aardvark Therapeutics in the 4th quarter valued at about $102,000.
Aardvark Therapeutics News Summary
Here are the key news stories impacting Aardvark Therapeutics this week:
- Negative Sentiment: HC Wainwright kept Aardvark Therapeutics on a Neutral rating with a $6.00 target, implying only limited upside from recent levels.
- Negative Sentiment: The analyst cut near-term earnings estimates, including Q2 2026 and Q3 2026, reinforcing expectations that the company will remain deeply unprofitable in the coming quarters.
- Negative Sentiment: FY2026 EPS was revised lower to ($3.80), and FY2027 is still expected to show a loss, which may pressure sentiment around AARD. HC Wainwright Neutral Rating and $6 Price Target on Aardvark Therapeutics
Aardvark Therapeutics Company Profile
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.
The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.
Featured Articles
- Five stocks we like better than Aardvark Therapeutics
- PayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued?
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
